# A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

> **NCT02399072** · — · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 202 (actual)

## Conditions studied

- Geographic Atrophy

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT02399072
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-30
- **Primary completion:** 2018-02-08
- **Final completion:** 2018-02-08
- **Target enrollment:** 202 (ACTUAL)
- **Why stopped:** There is no longer a plan to pursue an approval of lampalizumab.
- **Last updated:** 2019-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02399072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02399072, "A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02399072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*